SCHEMBL8158965

SCHEMBL8158965

C#CCCCCCCCCCCCc1ccco1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 1.00
CYP3A4 P08684 1/20 1.00
ALOX15 P16050 1/20 1.00
TDP1 Q9NUW8 2/20 0.54
USP2 O75604 1/20 0.54
HPGD P15428 1/20 0.54
CHRM2 P08172 1/20 0.41
MAOB P27338 1/20 0.38
EPHX2 P34913 3/20 0.36
KCNH3 Q9ULD8 1/20 0.35
CYSLTR2 Q9NS75 1/20 0.33
CYSLTR1 Q9Y271 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2D6 P10635 1/20 0.33
MAPT P10636 1/20 0.33
HTT P42858 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
SIGMAR1 Q99720 1/20 0.33
MAPK1 P28482 1/20 0.33
GLS O94925 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20878209 0.92 ALDH1A1 (0.86) ALDH1A1CYP3A4ALOX15TDP1USP2
SCHEMBL5804490 0.84
SCHEMBL7093157 0.84 ALDH1A1 (0.70) ALDH1A1CYP3A4ALOX15TDP1USP2
SCHEMBL7094868 0.82 ALDH1A1 (0.67) ALDH1A1CYP3A4ALOX15TDP1USP2
SCHEMBL16153546 0.81 ALDH1A1 (0.68) ALDH1A1CYP3A4ALOX15TDP1USP2
SCHEMBL16146034 0.81 ALDH1A1 (0.68) ALDH1A1CYP3A4ALOX15TDP1USP2
SCHEMBL16146035 0.81 ALDH1A1 (0.68) ALDH1A1CYP3A4ALOX15TDP1USP2
SCHEMBL11060991 0.77 ALDH1A1 (0.61) ALDH1A1CYP3A4ALOX15TDP1USP2
SCHEMBL3392080 0.76 ALDH1A1 (0.67) ALDH1A1CYP3A4ALOX15TDP1USP2
SCHEMBL3389147 0.76 ALDH1A1 (0.67) ALDH1A1CYP3A4ALOX15TDP1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260034186-A1 ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS RIZUN NODARI (US) 2026-02-05 US disclosed
US-20260027136-A1 CANNABIS BASED THERAPEUTIC AND METHOD OF USE YUZU LV LLC (US) 2026-01-29 US disclosed
US-12458653-B2 Cannabis based therapeutic and method of use YUZU LV LLC (US) 2025-11-04 US disclosed
US-12427176-B2 Enriched mineral pitch resin products and methods of manufacturing enriched mineral pitch resin products RIZUN NODARI (US) 2025-09-30 US disclosed
US-12303488-B2 Cannabis based therapeutic and method of use YUZU LV LLC (US) 2025-05-20 US disclosed
WO-2024263996-A2 COMPOUNDS AND METHODS FOR TREATING AGAINST NEMATODE INFECTIONS AND METHODS FOR COMPOUND DISCOVERY FOR SAME NEW YORK UNIVERSITY (US) 2024-12-26 WO disclosed
EP-4417252-A2 CANNABIS BASED THERAPEUTIC AND METHOD OF USE Yuzu LV LLC (US) 2024-08-21 EP disclosed
US-20240216457-A1 ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS RIZUN NODARI (US) 2024-07-04 US disclosed
US-20240216456-A1 ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS RIZUN NODARI (US) 2024-07-04 US disclosed
US-20240207344-A1 ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS RIZUN NODARI (US) 2024-06-27 US disclosed
US-7589121-B2 Use of furan alkyls for preparing a drug for treating obesity and cosmetically treating overweight LABORATOIRES EXPANSCIENCE (FR) 2009-09-15 US disclosed
US-20080219937-A1 purified furanic fraction of unsaponifiable of avocado, used for reducing, eliminating or preventing pigment spots, on the skin of a person LABORATOIRES EXPANSCIENCE (FR) 2008-09-11 US disclosed
US-20080219937-A1 purified furanic fraction of unsaponifiable of avocado, used for reducing, eliminating or preventing pigment spots, on the skin of a person LABORATOIRES EXPANSCIENCE (FR) 2008-09-11 US disclosed
US-20080081837-A1 Reducing glucose blood concentration and increasing tolerance with unsaponifiable avocado extract LABORATOIRES EXPANSCIENCE 2008-04-03 US disclosed
US-20080081837-A1 Reducing glucose blood concentration and increasing tolerance with unsaponifiable avocado extract LABORATOIRES EXPANSCIENCE 2008-04-03 US disclosed
US-20070281994-A1 Use Of Furan Alkyls For A Cellulite Cosmetic Treatment LABORATOIRES EXPANSCIENCE 2007-12-06 US disclosed
US-20070281994-A1 Use Of Furan Alkyls For A Cellulite Cosmetic Treatment LABORATOIRES EXPANSCIENCE 2007-12-06 US disclosed
US-20070238777-A1 Use of Furan Alkyls for Preparing a Drug for Treating Obesity and Cosmetically Treating Overweight LABORATOIRES EXPANSCIENCE 2007-10-11 US disclosed
US-20070238777-A1 Use of Furan Alkyls for Preparing a Drug for Treating Obesity and Cosmetically Treating Overweight LABORATOIRES EXPANSCIENCE 2007-10-11 US disclosed
US-6133313-A SPECIFIED AVOCADOFURANS SUCH AS 2-(TETRADECYL)FURAN, 2-(PENTADECYL)FURAN, 2-(HEXADECYL)FURAN, 2-(HEPTADECYL)FURAN, 2-(OCTADECYL)FURAN, 2-(1E-PENTADECENYL)FURAN, DERIVED FROM IDIOBLAST OIL CELLS OF AVOCADO; CONTROLLING SPODOPTERA EXIGUA THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2000-10-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070238777-A1 Use of Furan Alkyls for Preparing a Drug for Treating Obesity and Cosmetically Treating Overweight ACSL5, FASN, MC5R ALDH1A1 129/4885CYP3A4 223/4885ALOX15 26/4885
US-20080219937-A1 purified furanic fraction of unsaponifiable of avocado, used for reducing, eliminating or preventing pigment spots, on the skin of a person TYR, APEH, ALAD ALDH1A1 64/4885CYP3A4 1457/4885ALOX15 19/4885
US-20070281994-A1 Use Of Furan Alkyls For A Cellulite Cosmetic Treatment ACSL5, FASN, CUTA ALDH1A1 747/4885CYP3A4 1011/4885ALOX15 39/4885
US-20260027136-A1 CANNABIS BASED THERAPEUTIC AND METHOD OF USE CNR1, CNR2, OPRM1 ALDH1A1 1420/4885CYP3A4 1136/4885ALOX15 11/4885
US-20260034186-A1 ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS TRPV1, SOST, RUNX1 ALDH1A1 4768/4885CYP3A4 1979/4885ALOX15 121/4885
US-20080081837-A1 Reducing glucose blood concentration and increasing tolerance with unsaponifiable avocado extract FOS, IRS1, GPR119 ALDH1A1 1153/4885CYP3A4 567/4885ALOX15 130/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.